Tosedostat

also known as CHR 2797

Developed for: acute myeloid leukemia · myelodysplastic syndrome · cancer · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with multilineage dysplasia · acute myeloid leukemia, del(5q31-q32) · malignant pancreatic neoplasm · non-small cell lung carcinoma
+1 more
· plasma cell myeloma
Investigated by: Chroma Therapeutics · CTI BioPharma · National Cancer Institute (NCI) · Fred Hutchinson Cancer Center · Institute of Cancer Research, United Kingdom · M.D. Anderson Cancer Center
+3 more
· Quintiles, Inc. · Washington University School of Medicine · Weill Medical College of Cornell University

Trials 11 · a red edge is where a trial was stopped

today NCT02352831 · Ph 1/2 NCT02452346 · Ph 2 NCT01636609 · Ph 1 NCT01638442 · Ph 1 NCT01567059 · Ph 2 NCT01180426 · Ph 2 NCT00780598 · Ph 2 NCT00522938 · Ph 1/2 NCT00737555 · Ph 1 NCT00689000 · Ph 1/2 NCT00692354 · Ph 1

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 14 trials
Phase 1	NCT01636609	Nov 2012 → Jul 2019	acute myeloid leukemia, myelodysplastic syndrome	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 1	NCT01638442	Jun → Jul 2012	—	CTI BioPharma	Completed	No outcome recorded
Phase 1	NCT00737555	Aug 2006 → Mar 2008	cancer	Chroma Therapeutics	Completed	No outcome recorded
Phase 1	NCT00692354	Oct 2004 → Nov 2007	cancer	Chroma Therapeutics	Completed	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT02352831	Aug 2015 → Oct 2017	malignant pancreatic neoplasm	Washington University School of Medicine	Terminated	No outcome recorded
Phase 1/2	NCT00522938	Dec 2007 → Feb 2008	non-small cell lung carcinoma	Chroma Therapeutics	Terminated	No outcome recorded
Phase 1/2	NCT00689000	May 2006 → Dec 2007	acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma	Chroma Therapeutics	Completed	No outcome recorded
Phase 24 trials
Phase 2	NCT02452346	Mar 2015 → Oct 2017	myelodysplastic syndrome	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 2	NCT01567059	May 2012 → Jun 2013	acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with multilineage dysplasia, acute myeloid leukemia, del(5q31-q32), myelodysplastic syndrome	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01180426	Jun 2010 → Jun 2013	acute myeloid leukemia	Chroma Therapeutics	Unknown	No outcome recorded
Phase 2	NCT00780598	Oct 2009 → Mar 2011	acute myeloid leukemia	Chroma Therapeutics	Completed	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

Field	Value	Cited text
Known as	tosedostat	“An Open-label, Randomized, Two-way Crossover Trial of the Effect of a High-Fat Meal on the Pharmacokinetics of Oral Tosedostat (CHR 2797) in Healthy Male Subjects” NCT01638442 ↗ 8 “Proposed INN: tosedostat” NCT00737555 ↗ “CHR-2797 (tosedostat)” NCT00692354 ↗ “CHR-2797 (tosedostat)” NCT00522938 ↗ NCT01636609 ↗ NCT02352831 ↗ NCT01567059 ↗ NCT02452346 ↗ NCT00780598 ↗
Known as	CHR 2797	“An Open-label, Randomized, Two-way Crossover Trial of the Effect of a High-Fat Meal on the Pharmacokinetics of Oral Tosedostat (CHR 2797) in Healthy Male Subjects” NCT01638442 ↗ 6 NCT01638442 ↗ NCT00692354 ↗ NCT01180426 ↗ NCT00737555 ↗ NCT00689000 ↗ NCT00522938 ↗
Action	Inhibit	“Aminopeptidase Inhibitor” NCT00692354 ↗
Modality	Small molecule	— CHEMBL2103847 ↗
Route	Oral	“Once daily, oral ingestion of CHR-2797 capsules” NCT00522938 ↗